Prognosis and chemotherapy drug sensitivity in liver hepatocellular carcinoma through a disulfidptosis-related lncRNA...

Area of Science:

• Oncology
• Molecular Biology
• Cell Death Research

Background:

• Disulfidptosis is a novel regulated cell death mechanism linked to the actin cytoskeleton, offering potential cancer therapeutic strategies.
• The role of disulfidptosis-related lncRNAs (DRLs) in liver hepatocellular carcinoma (HCC) remains largely unexplored.

Purpose of the Study:

• To investigate the relationship between DRLs and HCC.
• To develop a prognostic model based on DRLs for HCC patients.
• To explore the association of this model with clinical outcomes, tumor mutation burden, and chemotherapy sensitivity.

Main Methods:

• Transcriptomic, clinical, and mutation data from TCGA HCC database were analyzed.
• DRLs were identified via correlation analysis.
• A prognostic model was constructed using Cox regression and LASSO, stratifying patients into high- and low-risk groups.
• Enrichment, immune infiltration, and tumor mutation burden analyses were performed.

Main Results:

• A six-DRL prognostic signature was developed, with high-risk patients exhibiting poorer prognosis.
• Significant differences in metabolic pathways and immune cell infiltration were observed between risk groups.
• High-risk and high tumor mutation burden (TMB) patients had the least favorable outcomes.
• Distinct chemotherapy drug sensitivities were noted between the risk groups.

Conclusions:

• A DRL-based signature provides predictive value for HCC prognosis.
• This signature may aid in optimizing chemotherapy drug selection for HCC patients.
• DRLs represent a promising area for HCC research and therapeutic development.